Berkley Resources Purchases Interest in TrichoScience Innovations

Berkley Resources Inc. (CNSX:BKS)(PINK SHEETS:BRKDF)(FRANKFURT:W8O) reports it
has purchased 200,000 common shares of Vancouver-based TrichoScience Innovations
Inc. at a price of CDN$1.00 per share. TrichoScience, a privately-held Life
Sciences company, has developed and patented a new hair cell replication
technology called Replicel(TM) that has the potential to become an effective,
non-surgical treatment for pattern baldness and other forms of hair loss in both
men and women. Berkley's share purchase represents 2.13% of TrichoScience's
issued and outstanding share capital.


The Replicel(TM) procedure is based on autologous cell implantation technology
that replicates a patient's hair cells from their own healthy hair follicles.
When reintroduced into areas of hair loss, the replicated cells initiate natural
hair regeneration. Replicel(TM) will undergo Stage 1 Human Clinical Trials
beginning in late 2010. For more information about TrichoScience and
Replicel(TM) visit www.trichoscience.com.


ABOUT BERKLEY RESOURCES INC.

Berkley is a growth-oriented and diversified venture company pursuing
opportunities in both Canada and the United States. The company's shares trade
on the Canadian National Stock Exchange (CNSX) under the symbol BKS and in the
U.S. under the symbol BRKDF.


For more information visit: www.berkleyresources.com.

ON BEHALF OF THE BOARD

Matt Wayrynen, President and Chief Executive Officer